Thyrocare Technologies Limited has provided prior intimation to the National Stock Exchange of India Limited and BSE Limited regarding a scheduled meeting of its Board of Directors.
The Board meeting is scheduled for Thursday, July 23, 2026. The primary agenda item for this meeting is to consider and approve the Unaudited Standalone and Consolidated Financial Results of the Company for the quarter ended June 30, 2026 (Q1 FY27).
The company has also disclosed that the trading window for dealing in the company's equity shares has been closed since July 1, 2026 for all Designated Persons and their immediate relatives. This closure is in compliance with:
- The provisions of the SEBI (Prohibition of Insider Trading) Regulations, 2015, as amended
- The Company's internal code of conduct to regulate, monitor and report trading by Designated Persons and their Immediate Relatives
The trading window will reopen 48 hours after the declaration of the Unaudited financial results for the quarter ended June 30, 2026 to the exchanges.